Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada on omeprazole

This article was originally published in The Tan Sheet

Executive Summary

Long-term use of Nexium does not increase the risk of cardiovascular events, Health Canada announces Feb. 27. Additionally, the agency says it is unable to conclude definitively whether long-term use of Losec (omeprazole) increases cardiovascular risk, and will continue to evaluate it if more data emerge. The agency recommends patients taking either drug not change their medication unless directed by their doctor, "as ulcers and reflux can lead to other complications if left untreated." FDA conducted its own safety review of the products in August after study results raised questions about long-term use of the drugs and cardiovascular outcomes. However, the agency concluded the data did not indicate the presence of a true effect (1"The Tan Sheet" Dec. 17, 2007, In Brief)...

You may also be interested in...



PPIs heart safe

Use of AstraZeneca's proton-pump inhibitor Prilosec (omeprazole) or the follow-on Nexium (esomeprazole) does not increase the risk of cardiovascular events, according to a Dec. 10 statement by FDA. The administration assessed two small, long-term studies on Prilosec and Nexium reported earlier this year - both of which had raised a question as to whether long-term use of the drugs increased the number of heart attacks, heart failures and heart-related sudden death - as well as 14 comparative studies of Prilosec, four of which were placebo-controlled. FDA announced in August that it was conducting the greater review of safety data but based on preliminary data, health-care providers and patients should not change their prescribing or use practices, respectively (1"The Tan Sheet" Aug. 13, 2007, p. 3). Based on the now complete comprehensive, scientific review, FDA concluded that the frequency of cardiovascular events seen in the earlier analyses does not indicate the presence of a true effect...

Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back

A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.

Balancing Act: China Approves Antiviral For Coronavirus While Promoting Traditional Medicines

Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.

Topics

UsernamePublicRestriction

Register

PS101406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel